| Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors A Moreira, C Loquai, C Pföhler, KC Kähler, S Knauss, MV Heppt, ... European Journal of Cancer 106, 12-23, 2019 | 226 | 2019 |
| The world of melanoma: epidemiologic, genetic, and anatomic differences of melanoma across the globe F Dimitriou, R Krattinger, E Ramelyte, MJ Barysch, S Micaletto, R Dummer, ... Current oncology reports 20, 1-9, 2018 | 173 | 2018 |
| Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations J Thalhammer, G Kindle, A Nieters, S Rusch, MRJ Seppänen, A Fischer, ... Journal of Allergy and Clinical Immunology 148 (5), 1332-1341. e5, 2021 | 102 | 2021 |
| Sarcoid-like reactions in patients receiving modern melanoma treatment F Dimitriou, AL Frauchiger, M Urosevic-Maiwald, MC Naegeli, ... Melanoma research 28 (3), 230-236, 2018 | 77 | 2018 |
| Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy F Dimitriou, S Hogan, AM Menzies, R Dummer, GV Long European Journal of Cancer 157, 214-224, 2021 | 75 | 2021 |
| Cytokine release syndrome during sequential treatment with immune checkpoint inhibitors and kinase inhibitors for metastatic melanoma F Dimitriou, AV Matter, J Mangana, M Urosevic-Maiwald, S Micaletto, ... Journal of Immunotherapy 42 (1), 29-32, 2019 | 51 | 2019 |
| Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors NG Nunez, F Berner, E Friebel, S Unger, N Wyss, JM Gomez, MT Purde, ... Med 4 (2), 113-129. e7, 2023 | 47 | 2023 |
| Pathogenesis and therapy of primary cutaneous T-cell lymphoma: Collegium Internationale Allergologicum (CIA) update 2020 M Bobrowicz, C Fassnacht, D Ignatova, YT Chang, F Dimitriou, ... International archives of allergy and immunology 181 (10), 733-745, 2020 | 47 | 2020 |
| Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy BR Halle, AB Warner, FY Zaman, A Haydon, P Bhave, AK Dewan, F Ye, ... Journal for immunotherapy of cancer 9 (10), 2021 | 41 | 2021 |
| Novel adjuvant options for cutaneous melanoma F Dimitriou, GV Long, AM Menzies Annals of Oncology 32 (7), 854-865, 2021 | 40 | 2021 |
| Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation I Saulite, D Ignatova, YT Chang, C Fassnacht, F Dimitriou, E Varypataki, ... Oncoimmunology 9 (1), 1738797, 2020 | 37 | 2020 |
| Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study F Dimitriou, K Namikawa, ILM Reijers, EI Buchbinder, JA Soon, ... Annals of Oncology 33 (9), 968-980, 2022 | 33 | 2022 |
| Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect J Boegeholz, CS Brueggen, C Pauli, F Dimitriou, E Haralambieva, ... BMC cancer 20, 1-15, 2020 | 30 | 2020 |
| Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma P Bhave, T Ahmed, SN Lo, A Shoushtari, A Zaremba, JM Versluis, ... Journal for immunotherapy of cancer 10 (7), 2022 | 27 | 2022 |
| Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study MC Brüggen, J Valencak, R Stranzenbach, N Li, R Stadler, C Jonak, ... Journal of the European Academy of Dermatology and Venereology 34 (7), 1489-1495, 2020 | 25 | 2020 |
| Frequency, treatment and outcome of immune-related toxicities in patients with immune-checkpoint inhibitors for advanced melanoma: results from an institutional database analysis F Dimitriou, R Staeger, M Ak, M Maissen, K Kudura, MJ Barysch, ... Cancers 13 (12), 2931, 2021 | 24 | 2021 |
| FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma F Dimitriou, SN Lo, AC Tan, L Emmett, R Kapoor, MS Carlino, GV Long, ... Annals of Oncology 33 (1), 99-106, 2022 | 22 | 2022 |
| Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity E Papadavid, E Kapniari, V Pappa, V Nikolaou, T Iliakis, M Dalamaga, ... British Journal of Dermatology 185 (5), 1035-1044, 2021 | 21 | 2021 |
| Double trouble: immunotherapy doublets in melanoma—approved and novel combinations to optimize treatment in advanced melanoma F Dimitriou, A Hauschild, JM Mehnert, GV Long American Society of clinical oncology educational book 42, 745-766, 2022 | 19 | 2022 |
| Update on adjuvant melanoma therapy F Dimitriou, RP Braun, J Mangana Current opinion in oncology 30 (2), 118-124, 2018 | 18 | 2018 |
